Clear Street upgraded Korro Bio (NASDAQ: KRRO) to “buy” from “hold” and raised its price target to $18.00 from $10.00, following Korro’s late January Analyst Day detailing their new lead program, KRRO-121 for hyperammonemia.
Analyst Bill Maughan, PhD, writes, “After further research, we believe the program clearly addresses an unmet need in the space, the scientific rationale behind the approach is strong, further validation of the mechanism’s ability to improve urea cycle disorders (UCDs) offer opportunities for value creation, potentially by 2027, and the competitive landscape (ex-KRRO-121) is not likely to advance treatment of the non-OTC-deficient UCDs in a meaningful timeframe.”
Hyperammonemia is due to insufficient clearance of ammonia from the blood stream. It manifests in multiple indications such as UCDs and hepatic encephalopathy (HE). UCDs are rare inborn errors of metabolism involving deficiencies of enzymes required for ureagenesis. The absence or deficiency of any of the urea cycle enzymes results in increased ammonia in the blood to dangerous levels. HE is a neuropsychiatric complication of liver disease characterized by cognitive dysfunction and altered consciousness. HE is primarily caused by the liver’s inability to detoxify ammonia. This leads to ammonia accumulating in the bloodstream and crossing the blood-brain barrier, causing brain dysfunction that ranges from subtle cognitive impairment to severe confusion and coma, significantly impacting patients’ quality of life. KRRO-121 is an RNA-editing oligonucleotide conjugated with GalNAc for the potential treatment of hyperammonemia in patients with UCD of any mutational background in adults and adolescents as well as patients with HE. Utilizing Korro’s proprietary OPERA platform, KRRO-121 is designed to stabilize a critical enzyme involved in reducing ammonia levels.
Dr. Maughan added that, “While management has described UCDs and HE as potentially addressable indications, UCDs are more clearly addressable by ‘121’s mechanism, in our opinion, and a much smaller patient population with orphan pricing. For now, we are choosing to model only the UCD opportunity, with the understanding that clinical progress in HE could result in largely unfactored value creation. And we look forward to the program’s entrance into the clinic after 2H26 regulatory submission.”
